Monoamine Oxidase Inhibition by Major Tanshinones from and Selective Muscarinic Acetylcholine M Receptor Antagonism by Tanshinone I.

Monoamine oxidases (MAOs) and muscarinic acetylcholine receptors (mAChRs) are considered important therapeutic targets for Parkinson's disease (PD). Lipophilic tanshinones are major phytoconstituents in the dried roots of that have demonstrated neuroprotective effects against dopaminergic neurotoxins and the inhibition of MAO-A. Since MAO-B inhibition is considered an effective therapeutic strategy for PD, we tested the inhibitory activities of three abundant tanshinone congeners against recombinant human MAO (hMAO) isoenzymes through in vitro experiments. In our study, tanshinone I () exhibited the highest potency against hMAO-A, followed by tanshinone IIA and cryptotanshinone, with an IC less than 10 µM. They also suppressed hMAO-B activity, with an IC below 25 µM. Although tanshinones are known to inhibit hMAO-A, their enzyme inhibition mechanism and binding sites have yet to be investigated. Enzyme kinetics and molecular docking studies have revealed the mode of inhibition and interactions of tanshinones during enzyme inhibition. Proteochemometric modeling predicted mAChRs as possible pharmacological targets of , and in vitro functional assays confirmed the selective M antagonist nature of (56.1% ± 2.40% inhibition of control agonist response at 100 µM). These findings indicate that is a potential therapeutic molecule for managing the motor dysfunction and depression associated with PD.